Author

M. Ardolino

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

M. Marotel· 2 shared M. S. Hasim· 2 shared A. Buchler· 1 shared A. C. Cheung· 1 shared A. Hagerman· 1 shared A. M. Crawley· 1 shared A. M. E. Ching· 1 shared A. McCurdy· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 19 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Marotel

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

CD8 T cell hyperfunction and reduced tumour control in models of advanced liver fibrosis

J. Madani, J. Li, A. Vranjkovic, K. Jorritsma, M. S. Hasim, M. Daneshmand, A. C. Cheung, A. M. E. Ching, J. E. Bruin, M. Ardolino, A. M. Crawley

This study shows that chronic liver fibrosis leads to systemic CD8+ T cell hyperfunction, impairing tumor control and immune response.

bioRxiv · Sep 20, 2023 · PreprintImmunology

More than a ligand: PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I interferon pathway.

J. Hodgins, J. Abou-Hamad, A. Hagerman, E. Yakubovich, C. Tanese De Souza, M. Marotel, A. Buchler, S. Fadel, M. Park, C. Fong-McMaster, M. J. F. Crupi, J. C. Bell, M.-E. Harper, B. Rotstein, R. Auer, , M. Ardolino

PD-L1 promotes oncolytic virus infection by inhibiting the type I interferon pathway through a metabolic shift involving enhanced glycolysis and lactate production.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology

A small molecule drug screening identifies colistin sulfate as an enhancer of Natural Killer cell cytotoxicity.

S. Cortes-Kaplan, M. Hasim, S. Kaczmarek, Z. Taha, G. Maznyi, S. McComb, S.-H. Lee, J.-S. Diallo, M. Ardolino

The paper screens FDA-approved drugs to find a small molecule that enhances NK cell cytotoxicity against cancer cells.

bioRxiv · Aug 20, 2021 · PreprintImmunology

When killers become thieves: trogocytosed PD-1 inhibits NK cells in cancer

M. S. Hasim, M. Marotel, J. J. Hodgins, E. Vulpis, H.-Y. Shih, A. Scheer, O. MacMillan, F. Alonso, K. Burke, D. P. Cook, M. T. Petrucci, A. Santoni, P. Fallon, A. Sharpe, G. Sciume, , M. Ardolino

Natural Killer cells acquire PD-1 from tumor cells via trogocytosis, which inhibits anti-tumor immunity.

bioRxiv · Jun 26, 2020Immunology